Back

Infection and Immunity nieuws

Jan 18: Tuberculosis vaccine does not protect vulnerable elderly against COVID-19

The BCG vaccine does not offer vulnerable elderly people protection against the symptoms of COVID-19. These are the initial results of the BCG-PRIME study among 6,132 vulnerable patients aged 60 and over. Research into the existing tuberculosis vaccine started in September 2020 and was carried out in 20 Dutch hospitals, including all UMCs and the Santeon top clinical hospitals.

Read more


International Trial of SARS-CoV-2 Convalescent Plasma Pauses Enrollment of Critically Ill COVID-19 Patients

The REMAP-CAP trial, which is testing the effects of convalescent plasma in COVID-19 patients with moderate and severe illness has paused enrollment for severely ill COVID-19 patients requiring intensive care unit (ICU) support.

Read more


Reduced mortality for sickest COVID-19 patients

Treating critically ill COVID-19 patients with drugs typically used for arthritis may significantly improve survival, a landmark study has found. The findings, which have not yet been peer-reviewed, come from the REMAP-CAP trial, which evaluates the effect of treatments on a combination of survival and length of time patients need support in an intensive care unit (ICU).

Read more


Dec 22: International Trials of Blood Thinners Pause Enrollment of Critically Ill COVID-19 Patients

Three clinical trial platforms working together to test the effects of full doses of anticoagulants (blood thinners) in COVID-19 patients have paused enrollment for one group of patients. Among critically ill COVID-19 patients requiring intensive care unit (ICU) support, therapeutic anticoagulation drugs did not improve outcomes. Enrollment continues for moderately ill hospitalized COVID-19 patients in the trials.

Read more


Dec 21: UMC Utrecht starts clinical trial with COVID-19 vaccine

UMC Utrecht will start a study with the COVID-19 candidate vaccine from CureVac on 28 December. A total of approximately 2,000 volunteers in the Netherlands will be recruited to participate in this study. The availability of multiple vaccines against corona is crucial to slow down and, if possible, stop the pandemic. Volunteers who want to participate in this study can register via www.vaccinatiestudie.nl.

Read more


Dec 15: Value of immune monitoring after stem cell transplantation in children

Immune monitoring of children after hematopoietic stem cell therapy may provide useful information to improve efficacy of treatment and reduce the occurrence of complications. In addition, immune monitoring may in the future be used for a personalized treatment in children undergoing hematopoietic cell transplantation.

Read more


Dec 12: Solution for chronic pain one step closer

Important steps have been taken at UMC Utrecht in understanding the cause of chronic pain associated with osteoarthritis and inflammation. This could also lead to new effective treatments in the future. More than 20 percent of the Dutch suffer from chronic pain. About 40 percent of this group has osteoarthritis. This type of chronic pain has been difficult to treat so far. Ramin Raoof obtained his PhD on 11 December for research into this.

Read more


Dec 11: Infections with Gram-negative bacteria responsible for significant mortality

Infections with Gram-negative bacteria form a significant burden of mortality in hospitalized patients in country with low antimicrobial resistance such as the Netherlands, contributing to more than 2,000 deaths per year. Of these, approximately one-third occur after non-bacteremic GNI and two-third after bacteremic GNI. These findings were presented by Tim Deelen in his PhD thesis that he defended at Utrecht University on December 11, 2020.

Read more


Dec 9: Using antibodies to fight bacteria

How can we use antibodies to fight bacteria? Suzan Rooijakkers, professor of microbiology at UMC Utrecht, has received a grant of € 2 million from the European Research Council (ERC) to answer this question. She has been awarded this grant for her research into antibody therapies that use the immune system to fight bacteria. In this way, she hopes to find an alternative to antibiotics in the long term.

Read more


Dec 4: Rapid antigen test for corona also reliable for screening asymptomatic people

The antigen rapid test is a reliable method to identify (early) corona infections in people without complaints and can therefore be used as screening in asymptomatic people. This was concluded in a validation study recently conducted by UMC Utrecht in Dutch professional football.

Read more